

Yang, James Chih-Hsin**Institution/Organization**

National Taiwan University Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

CHY

Disclosure of Potential Conflicts

CHY

COI Disclosure**Disclosures**

Amgen: advisory board or consultancy, Institutional

AstraZeneca: advisory or consultancy services, Principle investigator of the sponsored trial, investigator initiated studies; Institutional, Personal

Bayer: advisory or consultancy services, Institutional

Boehringer Ingelheim: advisory or consultancy services, Institutional , Personal

Bristol Myers Squibb: advisory or consultancy services, Institutional

Daiichi Sankyo: advisory or consultancy services, Institutional

Eli Lilly: advisory or consultancy services, Institutional

Hansoh Pharmaceuticals: advisory or consultancy services, Personal

Merck KGaA: advisory or consultancy services Institutional, Personal

Merck Sharp and Dohme: advisory or consultancy services, principle investigator of sponsored study. Institutional, Personal

Novartis: advisory or consultancy services Institutional, Personal

Ono Pharmaceuticals: advisory or consultancy services, Institutional

Pfizer: advisory or consultancy services, Institutional

Roche Genentech: advisory or consultancy services, Institutional, Personal

Takeda Oncology: advisory or consultancy services, Institutional, Personal

Yuhan Pharmaceuticals: advisory or consultancy services, Personal

Esai: advisory or consultancy services, Institutional

Janssen: advisory or consultancy services, Institutional

Taiwan Lung Cancer Society: speech, moderator, chairperson of conferences, Personal

Taiwan Oncology Society: speech, moderator, chairperson of conferences, Personal

COI Disclosure Certification

CHY

Confidentiality Agreement

CHY

Standards of Conduct Agreement

CHY

IASLC's Tax-Exempt Status

CHY

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?